Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
Targets |
DPP4[1]
|
---|---|
ln Vitro |
The primary renal catabolic route for GLP-1 in vivo is DPPIV, and GLP-1 functions as an inducer of satiety and a stimulant of glucose-dependent insulin secretion[2]. In pig proximal tubular cells, P32/98 hemifumarate in combination with 200 pM GLP-1 (10 μM; 3 h) does not significantly inhibit sodium re-absorption[2]. The mRNA expression of GLP-1R, DPPIV, Na+/H+ exchanger isoform 3 (NHE3), and sodium-dependent glucose transporters slc5a1, slc5a2 (SGLT1, 2) is not affected by P32/98 (10 μM; 96 h).
|
ln Vivo |
In Zucker diabetic fatty rats, a model of impaired glucose tolerance (IGT), long-term P32/98 (25 mg/kg; ig; once daily) therapy dramatically improves glucose tolerance[3].
|
Cell Assay |
Cell Cytotoxicity Assay[2]
Cell Types: Porcine proximal tubular cells Tested Concentrations: 10 μM Incubation Duration: 96 hrs (hours) Experimental Results: demonstrated no toxic. |
Animal Protocol |
Animal/Disease Models: Zucker diabetic fatty rat[2]
Doses: 25 mg/kg Route of Administration: Oral gavage; one time/day Experimental Results: Dramatically improved the glucose tolerance in Zucker diabetic fatty rats. |
References |
[1]. Augstein P, et al. Efficacy of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide (P32/98) in fatty Zucker rats with incipient and manifest impaired glucose tolerance. Diabetes Obes Metab. 2008;10(10):850-861.
[2]. Schlatter P, et al. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept. 2007 Jun 7;141(1-3):120-8. [3]. Wargent E, et al. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone. Diabetes Obes Metab. 2005;7(2):170-181. |
Molecular Formula |
C9H18N2OS
|
---|---|
Molecular Weight |
202.32
|
CAS # |
136259-20-6
|
Related CAS # |
P32/98 hemifumarate;251572-86-8
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
OC(/C=C/C(=O)O)=O.CCC(C(C(N1CCSC1)=O)N)C
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.9427 mL | 24.7133 mL | 49.4267 mL | |
5 mM | 0.9885 mL | 4.9427 mL | 9.8853 mL | |
10 mM | 0.4943 mL | 2.4713 mL | 4.9427 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.